ライフサイエンスコーパス: mouthwash

1 one exception, 60% of genes were altered by mouthwash.

2 standard care debridement and chlorhexidine mouthwash.

3 hwash; and 3) group III, chlorhexidine (CHX) mouthwash.

4 dine gluconate is more effective than herbal mouthwash.

5 vided a 30-second oral rinse and gargle with mouthwash.

6 oral cavity through the use of an antiseptic mouthwash.

7 ess longer-term efficacy and safety for both mouthwashes.

8 cola, and three types of alcohol-containing mouthwashes.

9 a suitable model for the biologic testing of mouthwashes.

10 t alternative for the biologic assessment of mouthwashes.

11 ssigned to three groups: 1) group I, placebo mouthwash; 2) group II, TRP mouthwash; and 3) group III,

12 nety-two patients were randomized to doxepin mouthwash (25 mg/5 mL water); 91 patients to diphenhydra

13 ents (4%); diphenhydramine-lidocaine-antacid mouthwash, 3 (4%); and placebo, 2 (2%).

14 Sera and saliva collected in mouthwash and Merocel sponges at day 1 and month 7 were

15 n) twice a day for seven days with a placebo mouthwash and then repeated this protocol with CHX mouth

16 ustrial products like candies, chewing gums, mouthwash and toothpaste.

17 personal care products such as toothpastes, mouthwashes and soaps.

18 ) viral load between any of the investigated mouthwashes and the control group (non-rinsing) at the e

19 ral carcinoma in a patient when applied as a mouthwash, and discriminate between fresh biopsied sampl

20 agents, 0.2% chlorhexidine gluconate, honey mouthwash, and saline, against six oral bacteria at conc

21 ning 0.2% chlorhexidine gluconate, an herbal mouthwash, and water in reducing the levels of viable ba

22 receive 0.2% chlorhexidine gluconate, herbal mouthwash, and water, respectively, as a preprocedural r

23 group I, placebo mouthwash; 2) group II, TRP mouthwash; and 3) group III, chlorhexidine (CHX) mouthwa

24 Decolonization involved chlorhexidine mouthwash, baths or showers with chlorhexidine, and nasa

25 1 in mouthwash by molecular absorption spectrometry and to th

26 s comparable with that of CHX mouthwash, TRP mouthwash can be considered a potential therapeutic agen

27 ant difference in tissue viability among the mouthwashes, cola, and negative control groups.

28 on age, sex, race/ethnicity, and time since mouthwash collection.

29 ning treatments, loose teeth, and the use of mouthwash, combined with demographic and risk factor cov

30 uthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose of placebo.

31 A common mouthwash comprising diphenhydramine-lidocaine-antacid i

32 Commercially available mouthwashes contain a variety of active ingredients that

33 Overall, this study demonstrates that mouthwash containing CHX is associated with a major shif

34 -19 patients was observed after rinsing with mouthwashes containing 0.2% CHX, 1.5% H(2)O(2), or CPC,

35 After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional

36 the presence of MCPyV DNA in 1 of 12 normal mouthwash DNAs.

37 authors show that, under the hypothesis that mouthwash does not increase the risk of oropharyngeal ca

38 Chlorhexidine mouthwash enhances treatment effects of conventional per

39 r in the biofilm compared with diffusion and mouthwashing exposures.

40 or 0.1% phosphate-buffered chlorine dioxide mouthwash for 1 minute.

41 s and were advised to use 0.2% chlorhexidine mouthwash for 1 week before being allocated to two group

42 a 1450-ppm fluoride toothpaste and a placebo mouthwash for 6 months.

43 ash and then repeated this protocol with CHX mouthwash for a further seven days.

44 We aimed to assess dexamethasone-based mouthwash for prevention of stomatitis in patients with

45 east cancer who were not given dexamethasone mouthwash for prevention of stomatitis).

46 ed as an active component in chewing gums or mouthwashes for both caries and gingivitis prevention.

47 s reported by 5 patients (6%) in the doxepin mouthwash group and no patients in the diphenhydramine-l

48 nts in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in the placebo group.

49 ours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine-l

50 nts in the diphenhydramine-lidocaine-antacid mouthwash group.

51 dinium chloride with zinc lactate (CPC + Zn) mouthwash in reducing gingival bleeding in patients with

52 igned to evaluate efficacy of triphala (TRP) mouthwash in reduction of plaque and gingivitis.

53 is study aimed to evaluate the efficacy of 3 mouthwashes in reducing severe acute respiratory syndrom

54 e and enables in vitro tests of disinfectant mouthwashes in simulated clinical use.

55 t smartphone app and sample collection using mouthwash increased efficiency and reduced cost.

56 Undiluted mouthwashes induced near-complete cell death 24 hours af

57 en consisting of DZA toothpaste and CPC + Zn mouthwash is effective in reducing gingival inflammation

58 iseptic formulations, including toothpastes, mouthwashes, lozenges, throat and nasal sprays, and as b

59 suggested that the use of alcohol-containing mouthwashes may increase the risk of oropharyngeal cance

60 e as nanocluster fillers, in nanocomposites, mouthwashes, medicines, and biomimetic dental materials.

61 ximum grade 3 adverse events for the doxepin mouthwash occurred in 3 patients (4%); diphenhydramine-l

62 e effect of 7-day use of chlorhexidine (CHX) mouthwash on the salivary microbiome as well as several

63 e the biologic effects of alcohol-containing mouthwashes on an engineered human oral mucosal model.

64 stigate the effect of commercially available mouthwashes on the survival and migratory capacity of hu

65 reatment group either received chlorhexidine mouthwash or advice to use it, but participants in the r

66 g the 4 hours after a single dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash

67 ad and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash

68 method on HPV genomic DNA detection in Scope mouthwash oral rinse samples and the reproducibility of

69 ng maternal periodontitis with chlorhexidine mouthwash plus SRP was associated with reduced risk of p

70 e consumption), oral hygiene (e.g. flossing, mouthwash), previous radiological diagnostic procedures

71 ne, a well-known antimicrobial agent used in mouthwash products and antiseptic creams, embedding the

72 and its association with 0.12% chlorhexidine mouthwash reduced peri-implant mucositis.

73 Dilutions of 15% to 20% for both CHX and EO mouthwashes resulted in 50% cell death.

74 Concentrations of 10% of both EO and CHX mouthwashes retained most of their antibacterial capacit

75 Mouthwash rinses yield a higher quality and quantity of

76 re collected from 29 participants, by use of mouthwash rinses, and were split into equal aliquots, wi

77 Of these, 136 patients (53%) had at least 1 mouthwashing sample that yielded Candida species other t

78 t effective method of DNA extraction of oral mouthwash samples for use in microbiome studies that uti

79 ng 16S rRNA gene sequencing in prediagnostic mouthwash samples from n = 81/160 EAC and n = 25/50 ESCC

80 nts, cancer free at baseline, with available mouthwash samples in 2 prospective cohort studies: (1) t

81 Using mouthwash samples of 989 individuals in two nationwide U

82 Mouthwash samples, obtained from a subset of patients, s

83 fication of the bacterial 16S rRNA gene from mouthwash samples.

84 s were compared with matched outdoor air and mouthwash samples.

85 h serum levels (for HPV-16, rho was 0.90 for mouthwash specimens and 0.92 for sponge specimens; for H

86 at month 7 (HPV-16 was detected in 93.2% of mouthwash specimens and 95.7% of sponge specimens; HPV-1

87 The alcohol-containing mouthwashes tested in this study do not cause significan

88 sts were treated with commercially available mouthwashes that contained either chlorhexidine (CHX) or

89 Conventional mouthwashes, though effective, are associated with adver

90 Young adults used a 5% or 10% TA mouthwash three times daily during OHR for 1 week.

91 vity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histo

92 n gingivitis was comparable with that of CHX mouthwash, TRP mouthwash can be considered a potential t

93 eathing, oral care (brushing teeth and using mouthwash twice daily), understanding (patient and famil

94 re instructed to rinse with their respective mouthwash twice daily.

95 and clinical trials have shown that chronic mouthwash use is associated with increased blood pressur

96 Their use is associated with mouthwash use.

97 sult in a spuriously elevated odds ratio for mouthwash use.

98 at least one confirmed dose of dexamethasone mouthwash) versus historical controls from the BOLERO-2

99 More drowsiness was reported with doxepin mouthwash vs placebo (by 1.5 points [95% CI, 0-4.0]; P =

100 oints (95% CI, 0.2-6.0; P = .02) for doxepin mouthwash vs placebo and 3.0 points (95% CI, 0.1-5.9; P

101 uthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly reduced oral mucositi

102 .004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo.

103 terial counts were done, and the MIC of each mouthwash was determined.

104 TRP mouthwash was found to decrease inflammatory parameters

105 In a randomized study, doxepin mouthwash was shown to reduce oral mucositis-related pai

106 Each mouthwash was tested over a range of concentrations for

107 on, a 30-s diffusive transport and simulated mouthwash were also performed.

108 t looking right, and use of dental floss and mouthwash were obtained during in-home interviews and va

109 and to the determination of eight metals in mouthwash, wine, cola, nitric acid, and water by ICP OES

110 plus 1.5% arginine and a fluoride-containing mouthwash with 0.075% CPC and 0.28% zinc lactate, and th